Mdxhealth Reports Third Quarter 2026 Financial Results

Michael K. McGarrity, Chief Executive Officer of mdxhealth

“As we communicated in our October preliminary update, our third quarter results reflect a temporary disruption in our commercial execution due to accelerated turnover within our sales organization. In direct response, we have initiated a restructuring of our commercial organization to reset our focus and process across our sales, marketing, and client services groups. By eliminating the Chief Commercial Officer role and effectively splitting our sales and marketing functions – both of which now report directly to me – we have established a vital check and balance on what had become a vertical operating structure, driving clear delineation and direct accountability for product strategy and sales execution while enhancing our customer experience. We have already made considerable progress in backfilling and rebuilding our sales team, and we are highly encouraged by the caliber of talent and industry experience we are attracting to mdxhealth. With selection, development, and retention serving as the foundation of our process through this commercial reset, we expect to exit the fourth quarter with a fully staffed and well-trained sales organization positioned to return to growth in 2027. We are confident that this commercial reset is both necessary and timely as we continue to advance our landmark PROTECT study with the University of Oxford and prepare to roll out our strategic AI initiatives in the first half of 2027. Supported by our operating teams' mandate of 'Quality First and Customers Always,' we remain committed to returning to the exemplary level of sales execution that has been the hallmark of our results over the last four years. Coupled with our proven track record of operating discipline, we are well-positioned to return mdxhealth to sustainable growth and adjusted EBITDA profitability as we continue to build on our unmatched vertical of clinically actionable precision diagnostics for our customers and patients in urologic cancers.”